HI
AVDL

Harbour Investments’s Avadel Pharmaceuticals AVDL Stock Holding History

Harbour Investments’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-300
Closed -$2K – 3719
2021
Q2 		$2K Buy
300
+100
+50% +$794 ﹤0.01% 3336
2021
Q1 		$2K Buy
+200
New +$1.62K ﹤0.01% 3177

Other funds holding AVDL

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Harbour Investments's AVDL Position: Q3 2021 in Review

Harbour Investments sold out of Avadel Pharmaceuticals (AVDL) in Q3 2021, closing a stake of 300 shares — an estimated $2K sold.

Harbour Investments first reported a position in AVDL in Q1 2021 and held it in 2 quarters. The position peaked at $2K in Q2 2021. 81 funds tracked by Wall St. Rank hold AVDL as of Q3 2021.

  • Harbour Investments reported no remaining Avadel Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Harbour Investments sold 300 Avadel Pharmaceuticals shares in Q3 2021, an estimated $2K.
  • Harbour Investments first reported a position in Avadel Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • Harbour Investments's Avadel Pharmaceuticals position peaked at $2K in Q2 2021.
  • 81 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2021.

Based on Harbour Investments's 13F filing for Q3 2021, filed 15 Nov 2021.